A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform.

Andrew RileyVictoria GreenRamsah CheahGordon McKenzieLaszlo KarsaiJames EnglandJohn Greenman

Published in: BMC cancer (2019)

The described microfluidic platform can maintain the viability of thyroid tissue slices ex vivo for a minimum of four days, providing a platform for the assessment of thyroid tissue radioiodine sensitivity/adjuvant therapies in real time.

Keyphrases

high throughput
single cell
circulating tumor cells
early stage
emergency department
label free
electronic health record
clinical evaluation